{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-059756","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.822500+00:00","generated_at":"2026-06-08T15:33:21.263255+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Stoke Therapeutics Q3 2023 net loss $24.5M; cash $214.7M funds into 2025","bullets":["Net loss of $24.5M ($0.55 per share) vs $26.1M ($0.66) in Q3 2022.","Revenue of $3.3M from Acadia license/services; cash runway to end of 2025.","STK-001 Phase 1/2a results plus OLE data expected Q1 2024; then regulatory meeting for Phase 3 design.","STK-002 Phase 1 study (OSPREY) for ADOA to start in UK early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-059756","json":"https://secwatch.observer/filing/0000950170-23-059756.json","markdown":"https://secwatch.observer/filing/0000950170-23-059756.md","text":"https://secwatch.observer/filing/0000950170-23-059756.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000095017023059756/0000950170-23-059756-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000095017023059756/stok-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T15:33:21.263255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f1becf89bdbf100a1f7e1d5f6ff15c8f8177c0b8","claim":"Stoke Therapeutics, Inc. reported three months ended September 30, 2023 results: revenue $3.3 million, net income -$24.5 million, EPS -$0.55 per share.","evidence_excerpt":"Revenue recognized for upfront license fees and services provided from a License and Collaboration Agreement with Acadia Pharmaceuticals for the three months ended September 30, 2023, was $3.3 million, compared to $2.9 million for the same period in 2022. • Net loss for the three months ended September 30, 2023, was $24.5 million, or $0.55 per share, compared to $26.1 million, or $0.66 per share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1623526/000095017023059756/0000950170-23-059756-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2023"},{"label":"Revenue","value":"$3.3 million"},{"label":"Net income","value":"-$24.5 million"},{"label":"EPS","value":"-$0.55 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}